Abstract 496P
Background
Indication for treatment with osimertinib after first/second generation epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) resistance depends on T790M mutation detected by re-biopsy. REMEDY trial consisting many cases using plasma biopsy revealed osimertinib introduction rate of approximately 25 percent in EGFR-mutant non-small cell lung cancer (NSCLC) patients pretreated with first/second generation EGFR-TKIs. The aim of study is to analyze the data on clinical practice of our hospital, where histological re-biopsy is actively carried out multiple times.
Methods
We retrospectively reviewed our electronic medical records of EGFR-mutant NSCLC patients to examine osimertinib introduction rate and associated outcomes.
Results
Among 95 patients with EGFR-mutant NSCLC, 73 patients received first/second generation EGFR-TKIs. Of 57 progressive disease patients, 50 patients (57/50: 87%) underwent re-biopsy. T790M was detected in 36 patients (36/50: 72%) and osimertinib was introduced in 35 patients (35/50: 70%). Among 36 patients harboring T790M mutation: histological re-biopsy was performed in 21 patients (21/36: 58%); cytology in 12 patients (12/36: 33%); blood biopsy in three patients (3/36: 8.3%). T790M was detected by first re-biopsy in 14 patients (14/36: 39%), and by second or subsequent re-biopsy 22 patients (22/36: 61%). The median overall survival (OS) in osimertinib induction patients was not reached (95% CI, 64.2-not reached) while in non- osimertinib patients median OS was 92.9 months (95% CI, 22.5-not reached) (p = 0.0173). Five year survival rates were 77% and 52%, respectively.
Conclusions
Higher osimertinib introduction rate was achieved by multiple repeated re-biopsy after first/second generation EGFR-TKIs, and its high introduction rate could contribute to better prognosis of EGFR-mutant NSCLC.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Kobe Minimally Invasive Cancer Center.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
457P - The prevalence of vitamin D deficiency in Thai cancer patients, its dynamics and association with cancer survival
Presenter: Chavapon Ngokngarm
Session: Poster display session
Resources:
Abstract
458P - Mutation tracking in circulating tumour DNA predicts relapse in completely resected EGFR-mutated NSCLC
Presenter: Martin Filipits
Session: Poster display session
Resources:
Abstract
460P - Mendelian randomization study showed no causality between metformin use and lung cancer risk
Presenter: Jiayi Shen
Session: Poster display session
Resources:
Abstract
461P - Blood trace minerals and lung cancer: A Mendelian randomization study
Presenter: Wei Xian
Session: Poster display session
Resources:
Abstract
463P - Prediction of invasiveness in lung adenocarcinoma using machine learning algorithm based on 3D-CT imaging
Presenter: Yusuke Saeki
Session: Poster display session
Resources:
Abstract
459P - Fish intake, dietary polyunsaturated fatty acids, and lung cancer: systematic review and dose-response meta-analysis of 1.7 million men and women
Presenter: Chao Cao
Session: Poster display session
Resources:
Abstract
462P - Usefulness for prevention of postoperative cerebrovascular complications in patients with lung cancer using carotid ultrasonography
Presenter: Sadanori Takeo
Session: Poster display session
Resources:
Abstract
468P - Histological type analysis of 10-year follow-up of WJTOG0105: A phase III study comparing second- and third-generation regimens with concurrent thoracic radiotherapy in unresectable stage III non-small cell lung cancer
Presenter: Masahiro Tsuboi
Session: Poster display session
Resources:
Abstract
469P - Comparison of combined chemoradiotherapy regimens; Paclitaxel plus carboplatin and cisplatin plus etoposide for locally advanced non-small cell lung cancer: A randomised phase III trial
Presenter: Alper Ata
Session: Poster display session
Resources:
Abstract
472P - Integration of expression rate and absolute cell counts of PD-1+ stromal tumour-infiltrating lymphocytes: Prognostic significance in esophageal squamous cell carcinoma
Presenter: Qingkun Song
Session: Poster display session
Resources:
Abstract